A placebo-controlled, double-blind, 2 x 2 factorial design, parallel- group, randomized clinical trial examining if chronic treatment of Huntington Disease (HD) with CoEnzyme Q10 and remacemide, alone or in combination, will slow down the progressive functional decline experienced by HD patients. Three hundred and forty stage I or II HD patients will be randomized to one of four treatment groups: CoEnzme Q10, remacemide, CoEnzyme Q10 and remacemide, double placebo. The subjects will be followed for 31 months for adverse events and for changes in vital signs, electrocardiogram, and surveillance laboratory tests. Neuropsychological and neurological tests will also be regularly performed as well as blood levels of CoEnzyme Q10 and remacemide. A subset of subjects will have brain lactate levels measured by magnetic resonance spectroscopy. The primary outcome variable is the change in total functional capacity from baseline to 30 months, and the analysis, assuming a 15% dropout rate, will have greater than 80% power to detect a 40% slowing of total functional capacity decline. An analysis of covariance with CoEnzyme Q10 treatment and remacemide treatment as factors of interest, investigator as the stratification factor and baseline total functional capacity as a covariant will be done. F-tests will be performed for significance of the main effects of CoEnzyme Q10 and remacemide and confidence intervals will be constructed for each of these effects. A two-sided significance of 0.05 will be used for each of these tests, and confidence coefficient of 0.95 will be used for interval estimation.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
United States
Zip Code
Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247
Zillikens, M Carola; Demissie, Serkalem; Hsu, Yi-Hsiang et al. (2017) Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nat Commun 8:80
James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4
Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668

Showing the most recent 10 out of 767 publications